

PRESS RELEASE

Cordlife partners with China Cord Blood Corporation to introduce services based on cellular technologies

- **Strengthens strategic alliance with China Cord Blood Corporation, the largest cord blood banking operator in China**
- **Leverage on economies of scale by expanding its geographical reach through partnerships and collaborations**

SINGAPORE, 11 November 2013 - Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a multi-product healthcare company catering to the mother and child segment, announced today that it has signed a non-binding term sheet with China Cord Blood Corporation (“CCBC”), to jointly explore and develop new services based on cellular technologies (the “Collaboration”).

Listed on the New York Stock Exchange (“NYSE”), CCBC is the largest cord blood banking operator in the People's Republic of China (the “PRC”) and has exclusive licences to provide cord blood storage services in the Beijing municipality and the provinces of Guangdong and Zhejiang. On November 12, 2012, Cordlife completed the acquisition of 10% of issued shares in CCBC.

Mr. Jeremy Yee, Executive Director and Group CEO of Cordlife said, “We actively seek opportunities to broaden our service offerings and expand our geographical coverage in the region through strategic acquisitions and partnerships with similar businesses that form a good fit with Cordlife. With this Collaboration, we will be able to leverage on CCBC’s resources to expand into new services, and CCBC will be able to leverage on our experience in developed markets in Asia.

This Collaboration is complementary to our previously announced proposed strategic alliance with Golden Meditech, which expanded our distribution network of products and services catering to the mother and child segment in the PRC. These two tie-ups will collectively strengthen our industry presence.”

Mr. Yuen Kam, Chairman of CCBC, said: “As the largest cord blood banking operator in the PRC, we are delighted to join forces with Cordlife in building a comprehensive pan-Asia platform for cord blood banking services. Together, we share a common mission, which is to improve the well being of the infants across Asia through our services. Cordlife

The initial public offering of Cordlife’s shares was sponsored by PrimePartners Corporate Finance Pte. Ltd., who assumes no responsibility for the contents of this release.

is a leading multi-product healthcare company catering to the mother and child segment and we believe that our collaboration will benefit parents throughout Asia.”

Mr. Yee concluded: “Helping parents secure their child’s future well-being is at the core of our service proposition. We are confident of increasing our share of the businesses in the fast growing markets across Asia. Overall, we remain focused on our key strategy to grow via economies of scale and scope through collaborative networks and strategic alliances.”

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and tissue banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore¹. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks. Cordlife completed the acquisition of the cord blood and cord tissue banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Life Corporation Limited (formerly known as Cordlife Limited) in June 2013.

Cordlife collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways. In May 2013, Cordlife Technologies Pte. Ltd., a wholly-owned subsidiary of Cordlife Group Limited, launched umbilical cord tissue banking service in Singapore. The storage and banking of umbilical cord tissue services provided in Singapore is currently not licensed by the Ministry of Health, Singapore. This service is provided on a research/clinical trial basis.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 24% share in Shandong Cord Blood Bank. In October 2013, Cordlife also acquired a 19.92% stake in StemLife Berhad, a fully licensed cord blood banking facility with the Ministry of Health Malaysia currently listed on the ACE Market of Bursa Malaysia.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; and Baby Kingdom Top 10

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

Family Brand Award 2012². In August 2013, Cordlife was presented with Merit Award for the Singapore Corporate Awards 2013, “Best Investor Relations Award”. In November 2013, Cordlife was awarded the prestigious SIAS Investors’ Choice Awards as winners in the “Most Transparent Company Award 2013” in the Retail & Household Goods Category and Mainboard Small Caps Category.

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543
CONTACT : Mr Gabriel Tan / Mr Kamal Samuel
OFFICE : 6438-2990
EMAIL : gabriel@financialpr.com.sg /
kamal@financialpr.com.sg

² Awarded to Cordlife (Hong Kong) Limited